Biotech & AI drug discoverySTAT — Biotech

STAT+: Incyte pancreatic cancer medicine induces lasting tumor responses, company says at ESMO

Incyte says a targeted drug of its, used in combination with chemotherapy, induced lasting tumor responses in certain patients with pancreatic cancer, as reported by the company at ESMO. The source offers limited further detail.

AI summary · generated only from source feed metadata; consult original

Source published2026-10-26T13:57:14+00:00

Published here2026-10-26T15:00:04+00:00

Original source

STAT — Biotech

Media report · consult original reporting

Read the original ↗https://www.statnews.com/2026/10/26/incyte-esmo-pancreatic-cancer-incb161734-results/

Original headline

STAT+: Incyte pancreatic cancer medicine induces lasting tumor responses, company says at ESMO

AI bilingual edit · consult original

Headlines are indexed or machine translated, not independent verification of scientific results. Medical news is not clinical advice. Distinguish interstellar concepts from demonstrated space technology using the original source.